ABS-1230
/ Jazz, Actio Biosciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 23, 2026
KYRON: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
(clinicaltrials.gov)
- P2 | N=45 | Recruiting | Sponsor: Actio Biosciences, Inc.
New P2 trial • CNS Disorders • Epilepsy • Pediatrics
1 to 1
Of
1
Go to page
1